The preclinical models have demonstrated that MEK inhibitor treatment induces immunogenic cell death, increases the levels of effector CD8+ T cells [121] and restores the surface expression of MHC-I and PD-L1 through STAT activation, thus enhancing tumor immunogenicity [122]. This evidence concerns the gene CD8A and neoplasm.